Skip to main content

IP Update: Apr 1, 2010

Premium

Title: RNA Interference in Respiratory Epithelial Cells

Patent Number: 7,687,475

Filed: Oct. 16, 2007

Lead Inventor: Paul McCray, University of Iowa

The invention, the patent's abstract states, "is directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules."


Title: Small Molecules Modulating Activity of microRNA Oligonucleotides and microRNA Targets and Uses Thereof

Patent Number: 7,687,616

Filed: May 14, 2004

Lead Inventor: Isaac Bentwich, Rosetta Genomics

The invention "describes a novel approach whereby small molecules may be used to modulate activity of microRNA and [genomic address messenger] oligonucleotides," the patent's abstract states. "This mode of therapy allows inter alia up-regulation of a disease-related target gene of novel GAM oligonucleotides of the … invention, by countering the activity of a GAM oligonucleotides [that] naturally inhibits expression of that target gene."


Title: Methods and Compositions Relating to Polypeptides with RNase III Domains That Mediate RNA Interference

Application Number: 20100075423

Filed: Sept. 14, 2009

Lead Inventor: Lance Ford, Ambion (Life Technologies)

The invention, the patent application's abstract states, "concerns methods and compositions involving RNase III and polypeptides containing RNase III domains to generate RNA capable of triggering RNA-mediated interference in a cell. In some embodiments, the RNase III is from a prokaryote. RNase III activity will cleave a double-stranded RNA molecule into short RNA molecules that may trigger or mediate RNAi. Compositions of the invention include kits that include an RNase III domain-containing polypeptide."

The invention further concerns "methods using polypeptides with RNase III activity for generating RNA molecules that effect RNAi, including the generation of a number of RNA molecules to the same target," the abstract adds.


Title: siRNA Targeting TATA Box-Binding Protein-Associated Factor

Application Number: 20100075869

Filed: Nov. 12, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TAF1."


Title: Sequence of dsRNA: ATN-RNA, Intervention Using iRNAi, Use of a Sequence of dsRNA: ATA-RNA, a Method of Treating and Inhibiting a Brain Tumor, a Kit for Inhibiting Cancer Cell [That] Expresses Tenascin, a Method for a Kit Preparation in a Brain Tumor Therapy

Application Number: 20100076053

Filed: July 30, 2007 PCT Filed: July 30, 2007

Lead Inventor: Jan Barciszewski, Polish Academy of Sciences (Senetek)

The invention, the patent application's abstract states, comprises "a sequence of double-stranded RNA … use of a sequence of double-stranded RNA … a method of treating a brain tumor, and a method of inhibiting brain tumor cells [that] express tenascin." The application also claims "a kit for inhibiting cancer cell [that] expresses tenascin and a method for a kit preparation in a brain tumor therapy.

"Malignant gliomas preferentially express a number of surface markers that may be exploited as therapeutic targets, including tenascin-C, an extracellular matrix glycoprotein that is ubiquitously expressed by malignant gliomas and probably contributes to tumor cell adhesion, invasion, migration, and proliferation," the abstract adds.


Title: Sensitization of Cancer Cells to Therapy Using siNA Targeting Genes from the 1P and 19Q Chromosomal Regions

Application Number: 20100076054

Filed: July 23, 2007 PCT Filed: July 23, 2007

Lead Inventor: Francois Berger, Joseph Fourier University

"The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference, and to their use as adjuvant in cancer therapy to sensitize cancer cells to conventional anticancer agents," the patent application's abstract states.


Title: Cationic Lipids and Uses Thereof

Application Number: 20100076055

Filed: April 16, 2009

Lead Inventor: Prasad Dande, Abbott

The invention, the patent application's abstract states, comprises "cationic lipids, cationic lipid-based drug delivery systems, ways to make them, and methods of treating diseases using them."


Title: Modified iRNA Agents

Application Number: 20100076056

Filed: July 27, 2009

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

"The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group," the patent application's abstract states. "The tether in turn can be connected to a selected moiety, e.g., a ligand [such as] a targeting or delivery moiety, or a moiety which alters a physical property. The cleavable linking group is one which is sufficiently stable outside the cell such that it allows targeting of a therapeutically beneficial amount of an iRNA agent, coupled by way of the cleavable linking group to a targeting agent, to targets cells, but which upon entry into a target cell is cleaved to release the iRNA agent from the targeting agent.

"The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity [such as] a lipophilic moiety. e.g., cholesterol, is directly, or indirectly, tethered," the abstract adds. "The invention also relates to methods of making and using such modified iRNA agents."


Title: Compositions and Methods for the Expression of Nucleic Acids

Application Number: 20100077495

Filed: Dec. 4, 2007 PCT Filed: Dec. 4, 2007

Lead Inventor: David Davis, Genentech

The patent application, its abstract states, claims "compositions and methods … for the expression of nucleic acids … [as well as] compositions and methods … for inducible expression of nucleic acids in transgenic cells and animals using transposon-based nucleic acid constructs. Compositions and methods are also provided herein for modulation of endogenous gene expression."


Title: Compositions and Methods for Blood-Brain Barrier Delivery in the Mouse

Application Number: 20100077498

Filed: Sept. 11, 2009

Lead Inventor: William Pardridge, Armagen Technologies

"The invention provides compositions and methods, for increasing transport of CNS-active agents across the blood-brain barrier in a mouse, e.g., a mouse model of a human CNS condition, while allowing their activity once across the barrier to remain substantially intact," the patent application's abstract states. "The CNS-active agents are transported across the blood-brain barrier via the mouse transferrin receptor. In some embodiments the agents are therapeutic, diagnostic, or research agents."

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.